Zobrazeno 1 - 10
of 22
pro vyhledávání: '"David F. Claxton"'
Autor:
Suming Huang, Dhimant Desai, Cesar Aliaga, Pavan Kumar Dhanyamraju, Sadie Steffens, Melanie A. Ehudin, Morgann Klink, Yali Ding, Mohammad Atiqur Rahman, Chunhua Song, Preeti Bhadauria, Arati Sharma, Chandrika Gowda, David F. Claxton, Soumya Iyer
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Simple Summary Acute Myeloid Leukemia is an aggressive disease with poor outcomes. New targeted therapies that can boost the effects of currently used chemotherapy medications without added toxicity are needed. Targeting an overactive kinase, called
Autor:
Todd E. Fox, Mark Kester, Hong Gang Wang, Shantu Amin, Charyguly Annageldiyev, Gemma Fabriàs, Jennifer M. Pearson, David J. Feith, Dhimant Desai, Thomas P. Loughran, José Luis Abad, Su Fern Tan, Myles C. Cabot, David F. Claxton, Arati Sharma
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Mol Cancer Res
instname
Mol Cancer Res
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. The 5-year survival rate is approximately 25%, and recent therapeutic developments have yielded little survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1bdd7205bbbd915f8f5818c777254c
http://hdl.handle.net/10261/212229
http://hdl.handle.net/10261/212229
Autor:
Amriti R. Lulla, Jeffrey J. Pu, Jawad Babar, Nadia Khan, Cyril H. Benes, Lanlan Zhou, Joshua E. Allen, A. Pieter J. van den Heuvel, Ultan McDermott, Mala K. Talekar, Mathew J. Garnett, C. Leah B. Kline, Junior Hall, Wolfgang Oster, David F. Claxton, Varun V. Prabhu, David T. Dicker, Wafik S. El-Deiry, Stephan A. Grupp
Publikováno v:
Cell Cycle. 17:468-478
ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ON
Autor:
Miki Kassai, Samy A.F. Morad, Li-Pin Kao, Traci S. Davis, Noha Abdelmageed, Gemma Fabriàs, Thomas P. Loughran, José L. Abad, Sarah Spiegel, Su Fern Tan, David J. Feith, Todd E. Fox, Mark Kester, Kelsey H. Fisher-Wellman, Matthew R. MacDougall, Myles C. Cabot, David F. Claxton
Publikováno v:
J Lipid Res
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
The combination of daunorubicin (dnr) and cytarabine (Ara-C) is a cornerstone of treatment for acute myelogenous leukemia (AML); resistance to these drugs is a major cause of treatment failure. Ceramide, a sphingolipid (SL), plays a critical role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4532efe4cdccaac86289135ec63a5056
http://hdl.handle.net/10261/189423
http://hdl.handle.net/10261/189423
Autor:
Thomas P. Loughran, Brian M. Barth, Mark Kester, Matthew R. MacDougall, Su-Fern Tan, Tonya N. Zeczycki, Todd E. Fox, Myles C. Cabot, David F. Claxton, P. Darrell Neufer, Traci S. Davis, Terence E. Ryan, David J. Feith, Tye G. Deering, Samy A.F. Morad
Publikováno v:
Journal of Lipid Research. 57:1231-1242
The objective of our study was to determine the mechanism of action of the short-chain ceramide analog, C6-ceramide, and the breast cancer drug, tamoxifen, which we show coactively depress viability and induce apoptosis in human acute myelogenous leu
Autor:
Hong Gang Wang, Christopher M. Dower, Kenichiro Doi, Qiang Liu, Shen Shu Sung, Krishne Gowda, David F. Claxton, Shantu Amin, Jyh Ming Lin, Thomas P. Loughran
Publikováno v:
Cancer Biology & Therapy. 15:1688-1699
Mcl-1, a pro-survival member of the Bcl-2 protein family, is an attractive target for cancer therapy. We have recently identified the natural product marinopyrrole A (maritoclax) as a novel small molecule Mcl-1 inhibitor. Here, we describe the struct
Autor:
David F. Claxton, Michelle A Levy
Publikováno v:
Expert opinion on investigational drugs. 26(3)
BCL-2 proteins are key players in the balance of cell life and death. Their roles in the development and biology of cancer have been well established and continue to be investigated. Understanding the mechanisms by which these proteins regulate apopt
Autor:
Brian M. Barth, Thomas P. Loughran, Krishne Gowda, Shantu Amin, Qiang Liu, Hong Gang Wang, David F. Claxton, Kenichiro Doi
Publikováno v:
Cancer Biology & Therapy. 15:1077-1086
Acute myeloid leukemia (AML) is one of the deadliest leukemias for which there is an urgent and unmet need for the development of novel treatment strategies. Multiple drug resistance mechanisms mediate poor drug response and relapse in patients, and
Autor:
Jong K. Yun, Dhimant Desai, Brian M. Barth, Thomas P. Loughran, Andy Awwad, Mark Kester, Hong Gang Wang, Stephen D. Turner, Xin Liu, Samy A.F. Morad, Edward H. Schuchman, Kenichiro Doi, David J. Feith, Arati Sharma, Ross L. Levine, Junjia Zhu, Todd E. Fox, Su Fern Tan, Alden Dewey, Myles C. Cabot, David F. Claxton, Barbara Spitzer, Mithun Vinod Shah, Shantu Amin, Jason Liao
Publikováno v:
Oncotarget
// Su-Fern Tan 1 , Xin Liu 2 , Todd E. Fox 3 , Brian M. Barth 4 , Arati Sharma 2 , Stephen D. Turner 5 , Andy Awwad 2 , Alden Dewey 2 , Kenichiro Doi 6 , Barbara Spitzer 7 , Mithun Vinod Shah 8 , Samy A.F. Morad 9, 10 , Dhimant Desai 11 , Shantu Amin
Autor:
Jianhong Zhang, Liuluan Zhu, W. Christopher Ehmann, Witold B. Rybka, Todd D. Schell, Melissa R. George, Yaxian Kong, David F. Claxton, Hong Zheng, Hui Zeng
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(12)
Purpose: T-cell immunoglobulin and immunoreceptor tyrosine–based inhibitory motif (ITIM) domain (TIGIT) is a recently identified T-cell coinhibitory receptor. In this study, we aimed to determine the clinical impact of TIGIT in patients with acute